目前和未来的JAK抑制剂状态
Donal P McLornan1, Janet E Pope2, Jason Gotlib3
1Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Lancet (London, England)
|August 29, 2021
概括
通过向JAK-STAT信号通路,雅努斯酶抑制剂正在彻底改变各种疾病的治疗方法. 这篇评论总结了它们的成功和安全性,并探讨了未来的治疗发展.
科学领域:
- 生物医学科学
- 药理学
- 免疫学
背景情况:
- 在许多疾病过程中,Janus 激酶 (JAK) 和信号转换器和转录激活器 (STAT) 途径至关重要.
- 使用JAK抑制剂对这些途径进行治疗已显示出显著的临床效用.
研究的目的:
- 审查各种JAK抑制剂的有效性和安全性的现有数据.
- 讨论基于JAK抑制剂的治疗方法的未来方向和潜在进展.
主要方法:
- 对JAK抑制剂的临床研究和治疗数据的文献评论.
- 综合有关治疗成功和不良事件的信息.
- 对未来的研究和临床应用进行假设分析.
主要成果:
- 雅克抑制剂在治疗骨髓增殖性瘤,类风湿性关节炎,炎症性肠病和皮肤病方面取得了显著的成功.
- 现有JAK抑制剂的安全性概况通常是很好的,每个药物都有特定的副作用.
- 从基础研究到临床应用已经实现了快速转化.
结论:
- 在多种疾病领域,JAK抑制剂代表了重大治疗进步.
- 持续的研究对于优化JAK抑制剂治疗和探索新的应用是必不可少的.
- 了解JAK-STAT信号对于开发下一代向疗法至关重要.
相关概念视频
The JAK-STAT Signaling Pathway
9.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.6K
Inhibition of Cdk Activity
5.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Dipeptidyl Peptidase 4 Inhibitors
300
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
300
Therapeutic Drug Monitoring: Overview and Classification
48
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
48
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
251
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
251
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


